Clinical trial NCT04289363: Emergency Department Outcomes for Patients With Opioid Use Disorder
Official title: Emergency Department Outcomes for Patients With Opioid Use Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Opioid-use Disorder
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2020-02-28
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will include ED patients.

Brief summary: Using mixed methods and triangulating multiples sources of data collected over the course of the parent (CTN-0079 - NCT03544112) and the ancillary studies to evaluate the feasibility, acceptability, sustainability and impact of the emergency department (ED)-initiated Buprenorphine (BUP) clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness.

Detailed description: The ancillary study will use mixed-methods combining quantitative and qualitative inquiry (interview/focus group and field notes) with administrative and health record data with some analyses including data collected from the parent CTN-0079 (NCT03544112) study. Further, qualitative data will be analyzed in the context of themes derived from CTN-0069 (NCT03023930) and CTN-0079. CTN-0079-A1 is planned to be conducted at two of the three sites of the parent study: (1) Catholic Medical Center, Manchester, New Hampshire; (2) Bellevue/NYU Health and Hospitals, New York, NY. Many of the methods, operating procedures, measures and forms will be retained or adapted from the parent study. However, CTN-0079-A1 is a new study in which lessons learned through the parent study have informed important design modifications necessary to improve study rigor and utility.

As in the parent study, CTN-0079, all clinical care (BUP and referral) will be delivered as part of each facility's clinical protocol, rather than as a research procedure. Implementation Facilitation (IF) activities will continue during ancillary trial preparation with a more intensive booster of IF activities occurring in the last month prior to trial commencement. Thereafter, all study IF support will cease and ancillary study data collection will begin. Data collection will occur over a course of approximately 12 months, divided into two 6-month study periods - the Post-IF and Maintenance Periods. A period of at least 6 months should separate the beginning of the Maintenance Period from the time of last study intervention.

Eligibility criteria: Inclusion Criteria:

Qualitative Population:

* Key stakeholder or opinion leader for ED-initiated BUP
* 18 years of age or older

Full Study Population \& Limited Study Population:

* Be able to speak English sufficiently to understand study procedures
* Be a potential candidate for ED-initiated BUP by meeting either of the 2 criteria:

  1. Clinical determination: patient is a willing and eligible candidate for ED-initiated BUP or for whom this can be reasonably inferred, including any patient who is administered and/or prescribed BUP as part of the index ED visit.
  2. Research determination: Both a and b below must be true at the time of study enrollment:

  a) Assessment conducted by an RA indicates that the patient- (all must be true): i. has had nonmedical opioid use within the last 7 days, ii. meets DSM-5 criteria for moderate or severe opioid use disorder (OUD), iii. denies methadone use within 72 hours of ED visit registration, iv. is not engaged in formal medications for opioid use disorder (MOUD) treatment, v. is not prescribed opioids for chronic pain management, vi. reports being interested or "not sure" if interested in receiving BUP as elicited on the ED Health Survey during the index ED visit.

  b) Absence of clinical documentation associated with the ED visit indicating that the patient is not a candidate for ED-initiated BUP.

Exclusion Criteria:

Qualitative Population:

* Unwilling or unable to provide consent
* currently in jail, prison, or any inpatient overnight facility

Full Study Population:

* Unwilling or unable to provide written/electronic informed consent
* Currently engaged in formal MOUD treatment at the time of index ED visit
* Currently in jail, prison or any inpatient overnight facility as required by court of law
* Previous participation as a patient- participant in CTN-0079 or previous participation as a Full Study participant in the current study
* Presents from a medical-based extended care facility
* Current research participant in a substance use intervention study
* Inadequate locator information (unable or unwilling to provide 2 unique means of contact)
* Unable or unwilling to complete research visits at baseline and Day 30.

Limited Study Population:

* Unwilling or unable to provide written/electronic informed consent
* Currently engaged in formal MOUD treatment at the time of index ED visit
* Currently in jail, prison or any inpatient overnight facility as required by court of law
* Previous participation in the current study as a Limited study or Full study participant
* Presents from a medical-based extended care facility

Primary outcomes:
measure: Percent of Participants Who Received Emergency Department (ED)-Initiated/Expedited Buprenorphine (BUP)
timeFrame: Up to Month 12
measure: Percent of Participants Who Received ED-Initiated/Expedited BUP Who Were Confirmed to be Engaged in Formal Addiction Treatment for Opioid Use Disorder (OUD) on the 30th Day Following Discharge
timeFrame: Day 30 Post-Discharge (Up to Month 12)
Secondary outcomes:
measure: Percent of Discharged Participants Who Received ED-Initiated BUP
timeFrame: Up to Month 12
measure: Percent of Not-Admitted Participants Who Received ED-Initiated BUP
timeFrame: Up to Month 12
measure: Percent of Participants Who Received ED-Initiated BUP
timeFrame: Up to Month 12
measure: Percent of Participants Who Received ED-Initiated/Expedited BUP
timeFrame: Up to Month 12
measure: Change in Number of Days of Opioid and/or Other Drug Use as Assessed by Timeline Followback (TLFB) Assessment
timeFrame: Baseline, Day 30
measure: Change in Number of Self-Reported Opioid-Related Overdose Events
timeFrame: Baseline, Day 30
Other outcomes:
Locations:
city: Manchester
country: United States
facility: Catholic Medical Center
state: New Hampshire
city: New York
country: United States
facility: Bellevue Hospital Center
state: New York
Study officials:
affiliation: NYU Langone Health
name: Ryan McCormack, MD, MS
role: PRINCIPAL_INVESTIGATOR
References: